Prevention of nitrate tolerance with angiotensin II receptor type 1 blocker in patients with stable angina: Yet another failed strategy to prevent tolerance

Cardiovascular Drugs and Therapy

Volumn 18, Issue 5, 2004, Pages 339-342

  Thadani, Udho ^a,b  

^a UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

^b WP 3120 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE; ALPHA TOCOPHEROL; ANGIOTENSIN RECEPTOR ANTAGONIST; ARGININE; ASCORBIC ACID; CANDESARTAN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FOLIC ACID; GLYCERYL TRINITRATE; ISOSORBIDE 5 NITRATE; ISOSORBIDE DINITRATE; LOSARTAN; ORGANIC NITRATE; SUPEROXIDE DISMUTASE;

BLOOD VESSEL REACTIVITY; CLINICAL TRIAL; DRUG SAFETY; DRUG TOLERANCE; EDITORIAL; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; NONHUMAN; PRIORITY JOURNAL; SIDE EFFECT; STABLE ANGINA PECTORIS; TACHYPHYLAXIS; TREATMENT FAILURE;

ANGINA PECTORIS; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DRUG TOLERANCE; HUMANS; NITROGLYCERIN; VASODILATOR AGENTS;

EID: 17644392116     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-005-5056-x     Document Type: Editorial

References (48)

1. Brunton TL. Use of nitrate of amyl in angina pectoris. Lancet 1987;2:628-629.
2. Goldstein RE, Rosing DR, Redwood DR, et al. clinical and circulatory effects of isosorbide dinitrate: Comparison with nitroglycerin. Circulation 1971;43:629-640.
3. Thadani U, Parker JO. Influence of glyceryltrinitrate during supine and upright exercise in patients with angina pectoris. Br Heart J 1978;40:1229-1236.
4. Thadani U, Fung HL, Darke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose-response relationship and duration of action during acute therapy. Circulation 1980;62:491-502.
5. Thadani U, Manyari D, Parker JO, Fung HL. Tolerance to the circulatory effects of oral isosorbide dinitrate: Rate of development and cross tolerance to glyceryl trinitrate. Circulation 1980b;61:526-535.
6. Thadani U, Fung HL, Karke AC, Parker JO. Oral isosorbide dinitrate in angina pectoris: Comparison of duration of action and dose-response relation during acute and sustained therapy. Am J Cardiol 1982;49:411-419.
7. Parker JO, Jung HL. Transdermal nitroglycerin in angina pectoris. Am J Cardiol 1984;54:471-476.
8. Thadani U, Hamilton SF, Olson E, et al. Transdermal nitroglycerin patches in angina pectoris. Annals of Internal Medicine 1986;105:485-492.
9. Steering Committee, Transdermal Nitroglycerin Cooperative Study. Acute and chronic antianginal efficacy of continuous twenty-four hour application of transdermal nitroglycerin. Am J Cardiol 1991;68:1263-1273.
10. Parker JO, Farrell B, Lahey KA, Moe G. Effect of intervals between doses on the development of tolerance to isosorbide dinitrate. N Eng J Med 1987;316:1440-1444.
11. Thadani U, Hamilton SF, Olson E, et al. Duration of effects and tolerance of slow release isosorbide-5-mononitrate for angina pectoris. Am J Cardiol 1987a;59:756-762.
12. Thadani U, Prasad R, Hamilton SF, et al. Usefulness of twice daily isosorbide-5-mononitrate in preventing development of tolerance in angina pectoris. Am J Cardiol 1987c;60:477-482.
13. Zimrin D, Reichek N, Bogin K, et al. Antianginal effects of intavenous nitroglycerin. Circulation 1988;77:1376-1384.
14. Cowan JC, Bourke JP, Reid DS. Prevention of tolerance to nitroglycerin patches by overnight removal. Am J Cardiol 1987;60:271-275.
15. DeMots H, Glasser SP. Intermittent transdermal nitroglycerin therapy in the treatment of chronic stable angina. J Am Coll Cardiol 1989;13:786-795.
16. Thadani U, Lipicky RJ. Short and long acting oral nitrates for stable angina pectoris. Cardiovasc Drugs Ther 1994;8:611-623.
17. Thadani U, Lipicky RJ. Ointments and transdermal nitroglycerin patches for stable angina pectoris. Cardiovasc Drugs Ther 19948:625-633.
18. Thadani U. Treatment of stable angina. Curr Opin Cardiol 1999;14:349-358.
19. Thadani U. Nitrate Tolerance, Rebound and their clinical relevance in stable angina pectoris, unstable angina and heart failure. Cardiovasc Drugs Ther 1996;10:735-742.
20. Parker JO, Van Koughnott KA, Fung HL. Transdermal isosorbide dinitrate in angina pectoris. Am J Coll Cardiol 1984;54:8-13.
21. Kowaluk E, Hough K, Fung H-L. Effect of intermittent exposure and drug-free intervals in the in-vitro vascular tolerance to nitroglycerin. Life Sci 1989;44:1157-1163.
22. Crandall LA, Leak CD, Loventhart AS, et al. Acquired tolerance to and cross tolerance between the nitric acid esters and sodium nitrite in man. J Pharmacol Experimental Ther 1931;41:103-119.
23. Ignarro LJ, Lippton H, Edwards JE, et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: Evidence for the involvement of S-nitrosothiole as active intermediates. J Pharmacol Experimental Ther 1981;218:739-748.
24. Needleman P, Johnson EM Jr. Mechanism of tolerance development to organic nitrates. Pharmacology and Experimental Therapeutics 1973;184:709-715.
25. Dupuis J, Lalonde G, Lemieux R, et al. Tolerance to intravenous nitroglycerin in patients with congestive heart failure: Role of increased intravascular volume, neurohumoral activation and lack of prevention with N-acetylcysteine. J Am Coll Cardiol 1990;16:923-931.
26. Chen Z, Zhang J, Stamier JS. Identification of the enzymatic mechanism of nitroglycerin bioactivation. PNAS 2002;99(12):8306-1311.
27. Parker JD, Farrell B, Fenton T, et al. Counter-regulatory responses to continuous and intermittent therapy with nitroglycerin. Circulation 1991;84:2336-2345.
28. Sage PR, de la Lande IS, Stafford I, et al. Nitroglycerin tolerance in human vessels: Evidence for impaired nitroglycerin bioconversion. Circulation 2000;102:2810-2815.
29. Wang EQ, Lee WI, Brazeau D, et al. cDNA microarray analysis of vascular gene expression after nitric oxide donor infusion s in rats: Implications for nitrate tolerance mechanisms. AAPS Pharm Sci 2002;4(2):1-11.
30. Frame MD, Fox RJ, Kim D, et al. Diminished Arteriolar Responses in nitrate tolerance involve ROS and angiotensin II. Am J Physiol Heart Circ Physiol 2202;282:H2377-H2385.
31. Munzel T, Giaid A, Kurz S, et al. Evidence for a role of endothelin 1 and kinase C in nitroglycerin tolerance. Proc Natl Acad Sci USA 1995;92:5244-5248.
32. Kurz S, Hink U, Nickenig G, et al. Evidence for a causal role of the renin-angiotensin system in nitrate tolerance. Circulation 1999:99(24);3181- 3187.
33. Loscalzo J. Folate and nitrate-induced endothelial dysfunction: A simple treatment for a complex pathobiology. Circulation 2001;1004:1086-1088.
34. Munzel T, Mulsch A, Kleschyov A. Mechanisms underlying nitroglycerin-induced superoxide production in platelets: Some insight, more questions. Circulation 2002;106:170-172.
35. Munzel T, Sayegh H, Freeman B, et al. Evidence for enhanced vascular superoxide anion production in nitrate tolerance: A novel mechanism underlying tolerance and cross-tolerance. J Clin Invest 1995;95:187-194.
36. Gori T, Parker JD. Nitrate tolerance: A unifying hypothesis. Circulation 2002;106:2510-2513.
37. Katz R, Levy WS, Buff L, et al. Prevention of nitrate tolerance with angiotension converting enzyme inhibitors. Circulation 1991;83:1271-1277.
38. Munzel T, Bassenge E. Long-term angiotensin-converting enzyme inhibition with high-dose enalapril retards nitrate tolerance in large epicardial arteries and prevents rebound coronary vasoconstriction in vivo. Circulation 93(11);1996:2052-2058.
39. Dakak N, Makhoul N, Flugelman MY, et al. Failure of captopril to prevent nitrate tolerance in congestive heart failure secondary to coronary artery disease. Am J Cardiol 1990;66:608-613.
40. Parker JD, Parker JO. Effect of therapy with an angiotensin-converting enzyme inhibitor on hemodynamic and counter-regulatory responses during continuous therapy with nitroglycerin. J Am Coll Cardiol 1993;21:1445-1453.
41. Harai N, Kawano H, Yasue H, et al. Attenuation of nitrate tolerance and oxidative stress by an angiotensin II receptor blocker in patients with coronary spastic angina. Circulation 2003;108:1446-1450.
42. Cotter G, Metzkor-Cotter E, Kaluski E, et al. Usefulness of losartan, captopril, and furosemide in preventing nitrate tolerance and improving control of unstable angina pectoris. Am J Cardiol 1998;82:1024-1029.
43. Milone SD, Azevedo ER, Forster C, et al. The angiotensin II-receptor antagonist losartan does not prevent hemodynamic or vascular tolerance to nitroglycerin. J Cardiovasc Pharmacol 1999;34(5):645-650.
44. Longobardi G, Ferrara N, Leosco D, et al. Angiotensin II-receptor antagonist losartan does not preventg nitroglycerin tolerance in patients with coronary artery disease. Cardiovasc Drugs Ther 2004;18:363-370.
45. Gori T, Burstein JM, Ahmed S, et al. Folic acid prevents nitroglycerin-induced nitric oxide synthase dysfunction and nitrate tolerance: A human in vivo study. Circulation 2001;104:1119-1123.
46. McVeigh GE, Hamilton P, Wilson M, et al. Platelet nitric oxide and superoxide release during the development of nitrate tolerance: Effect of supplemental ascorbate. Curculation 2002;106:208-213.
47. Hideki W, Masaaki K, Sadanori O, et al. Randomized, double-blind, placebo-controlled study of supplemental vitamin E on Attenuation of the Development of Nitrate Tolerance. Circulation 1997;96(8):2545-2550.
48. Parker JO, Parker JD, Caldwell RW, et al. The effect of supplemental 1-arginine on tolerance development during continuous transdermal nitroglycerin therapy. J Am Coll Cardiol 2002;2002:1199-1203.